Dabur set to export cancer drugs to Pakistan and Turkmenistan
Indian drugmaker Dabur Pharma is set to expand into the cancer drug segment of the Pakistan and Turkmenistan markets, after the Pakistani government decided to allow imports from India. The Ministry of Health in Islamabad has issued approvals for two local companies - Atco Pharma and AJ Mizra - to import from Darbur. The firm has also started making deliveries to Turkmenistan from its facility in Himachal Pradesh. Dabur chairman Mohit Burman said that the Commonwealth of Independent States, Southeast Asia and Latin America were priority markets for export, as well as Kazakhstan, Georgia and Moldova.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze